Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations Article Swipe
Yutaka Yamada
,
Hisao Imai
,
Tomohide Sugiyama
,
Hiroyuki Minemura
,
Kenya Kanazawa
,
Takashi Kasai
,
Koichi Minato
,
Kyoichi Kaira
,
Takayuki Kaburagi
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.3390/medicina57090929
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.3390/medicina57090929
Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive EGFR mutations. However, the effectiveness of EGFR-TKI rechallenge after first-line EGFR-TKI treatment is not sufficient in elderly patients (over 75 years of age) harboring drug-sensitive EGFR mutations. Therefore, we investigated the effectiveness and safety of EGFR-TKI rechallenge after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations. Materials and Methods: Between April 2008 and December 2015, we analyzed 78 elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations with first-line EGFR-TKI treatment at four Japanese institutions. We retrospectively evaluated the clinical effectiveness and safety profiles of EGFR-TKI rechallenge after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation). Results: Twenty-two patients in the cohort were rechallenged with EGFR-TKI. The median age was 79.5 years (range 75–87 years). Despite the fact that it was a retrospective analysis, even with EGFR-TKI rechallenge treatment the response rate was 23%, progression-free survival was 5.3 months, and overall survival was 14.4 months. Common adverse events included rash acneiform, paronychia, diarrhea, and anorexia. There were no treatment-related deaths. Due to the occurrence of adverse events of grade 2 or more, dose reduction was performed in 15 (68.2%) of 22 cases. Conclusions: EGFR-TKI rechallenge treatment after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations was one of the limited, safe and effective treatment options for elderly EGFR-positive lung cancer patients.
Related Topics
Concepts
Medicine
Erlotinib
Internal medicine
Oncology
Lung cancer
Gefitinib
Epidermal growth factor receptor
Rash
Adverse effect
Retrospective cohort study
EGFR inhibitors
Tyrosine-kinase inhibitor
Drug
Cancer
Pharmacology
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/medicina57090929
- https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891
- OA Status
- gold
- Cited By
- 6
- References
- 54
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3198727144
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3198727144Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/medicina57090929Digital Object Identifier
- Title
-
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR MutationsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-09-03Full publication date if available
- Authors
-
Yutaka Yamada, Hisao Imai, Tomohide Sugiyama, Hiroyuki Minemura, Kenya Kanazawa, Takashi Kasai, Koichi Minato, Kyoichi Kaira, Takayuki KaburagiList of authors in order
- Landing page
-
https://doi.org/10.3390/medicina57090929Publisher landing page
- PDF URL
-
https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891Direct OA link when available
- Concepts
-
Medicine, Erlotinib, Internal medicine, Oncology, Lung cancer, Gefitinib, Epidermal growth factor receptor, Rash, Adverse effect, Retrospective cohort study, EGFR inhibitors, Tyrosine-kinase inhibitor, Drug, Cancer, PharmacologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
6Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 4, 2023: 1, 2022: 1Per-year citation counts (last 5 years)
- References (count)
-
54Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3198727144 |
|---|---|
| doi | https://doi.org/10.3390/medicina57090929 |
| ids.doi | https://doi.org/10.3390/medicina57090929 |
| ids.mag | 3198727144 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/34577852 |
| ids.openalex | https://openalex.org/W3198727144 |
| fwci | 1.06123945 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000368 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Aged |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000369 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Aged, 80 and over |
| mesh[2].qualifier_ui | Q000188 |
| mesh[2].descriptor_ui | D002289 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | drug therapy |
| mesh[2].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[3].qualifier_ui | Q000235 |
| mesh[3].descriptor_ui | D002289 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | genetics |
| mesh[3].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[4].qualifier_ui | Q000235 |
| mesh[4].descriptor_ui | D066246 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | genetics |
| mesh[4].descriptor_name | ErbB Receptors |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D006801 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Humans |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D008175 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Lung Neoplasms |
| mesh[7].qualifier_ui | Q000235 |
| mesh[7].descriptor_ui | D008175 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | genetics |
| mesh[7].descriptor_name | Lung Neoplasms |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D009154 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Mutation |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D004364 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Pharmaceutical Preparations |
| mesh[10].qualifier_ui | Q000009 |
| mesh[10].descriptor_ui | D047428 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | adverse effects |
| mesh[10].descriptor_name | Protein Kinase Inhibitors |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D012189 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Retrospective Studies |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000368 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Aged |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000369 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Aged, 80 and over |
| mesh[14].qualifier_ui | Q000188 |
| mesh[14].descriptor_ui | D002289 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | drug therapy |
| mesh[14].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[15].qualifier_ui | Q000235 |
| mesh[15].descriptor_ui | D002289 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | genetics |
| mesh[15].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[16].qualifier_ui | Q000235 |
| mesh[16].descriptor_ui | D066246 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | genetics |
| mesh[16].descriptor_name | ErbB Receptors |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D006801 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Humans |
| mesh[18].qualifier_ui | Q000188 |
| mesh[18].descriptor_ui | D008175 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | drug therapy |
| mesh[18].descriptor_name | Lung Neoplasms |
| mesh[19].qualifier_ui | Q000235 |
| mesh[19].descriptor_ui | D008175 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | genetics |
| mesh[19].descriptor_name | Lung Neoplasms |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D009154 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Mutation |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D004364 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Pharmaceutical Preparations |
| mesh[22].qualifier_ui | Q000009 |
| mesh[22].descriptor_ui | D047428 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | adverse effects |
| mesh[22].descriptor_name | Protein Kinase Inhibitors |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D012189 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Retrospective Studies |
| type | article |
| title | Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations |
| biblio.issue | 9 |
| biblio.volume | 57 |
| biblio.last_page | 929 |
| biblio.first_page | 929 |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T11067 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9976000189781189 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Colorectal Cancer Treatments and Studies |
| topics[2].id | https://openalex.org/T12334 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9957000017166138 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Lung Cancer Research Studies |
| is_xpac | False |
| apc_list.value | 1800 |
| apc_list.currency | CHF |
| apc_list.value_usd | 1949 |
| apc_paid.value | 1800 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 1949 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9107142090797424 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778087573 |
| concepts[1].level | 4 |
| concepts[1].score | 0.694541871547699 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q418369 |
| concepts[1].display_name | Erlotinib |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6826705932617188 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6736696362495422 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C2776256026 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6509350538253784 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[4].display_name | Lung cancer |
| concepts[5].id | https://openalex.org/C2780580887 |
| concepts[5].level | 4 |
| concepts[5].score | 0.6156190037727356 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q417824 |
| concepts[5].display_name | Gefitinib |
| concepts[6].id | https://openalex.org/C2779438470 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5939536094665527 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[6].display_name | Epidermal growth factor receptor |
| concepts[7].id | https://openalex.org/C2778570526 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5217821598052979 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q653197 |
| concepts[7].display_name | Rash |
| concepts[8].id | https://openalex.org/C197934379 |
| concepts[8].level | 2 |
| concepts[8].score | 0.508391797542572 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[8].display_name | Adverse effect |
| concepts[9].id | https://openalex.org/C167135981 |
| concepts[9].level | 2 |
| concepts[9].score | 0.47787800431251526 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[9].display_name | Retrospective cohort study |
| concepts[10].id | https://openalex.org/C2777506169 |
| concepts[10].level | 4 |
| concepts[10].score | 0.44712668657302856 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[10].display_name | EGFR inhibitors |
| concepts[11].id | https://openalex.org/C2778820342 |
| concepts[11].level | 3 |
| concepts[11].score | 0.44543248414993286 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q906415 |
| concepts[11].display_name | Tyrosine-kinase inhibitor |
| concepts[12].id | https://openalex.org/C2780035454 |
| concepts[12].level | 2 |
| concepts[12].score | 0.42146509885787964 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[12].display_name | Drug |
| concepts[13].id | https://openalex.org/C121608353 |
| concepts[13].level | 2 |
| concepts[13].score | 0.338359534740448 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[13].display_name | Cancer |
| concepts[14].id | https://openalex.org/C98274493 |
| concepts[14].level | 1 |
| concepts[14].score | 0.23474910855293274 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[14].display_name | Pharmacology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9107142090797424 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/erlotinib |
| keywords[1].score | 0.694541871547699 |
| keywords[1].display_name | Erlotinib |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.6826705932617188 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.6736696362495422 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/lung-cancer |
| keywords[4].score | 0.6509350538253784 |
| keywords[4].display_name | Lung cancer |
| keywords[5].id | https://openalex.org/keywords/gefitinib |
| keywords[5].score | 0.6156190037727356 |
| keywords[5].display_name | Gefitinib |
| keywords[6].id | https://openalex.org/keywords/epidermal-growth-factor-receptor |
| keywords[6].score | 0.5939536094665527 |
| keywords[6].display_name | Epidermal growth factor receptor |
| keywords[7].id | https://openalex.org/keywords/rash |
| keywords[7].score | 0.5217821598052979 |
| keywords[7].display_name | Rash |
| keywords[8].id | https://openalex.org/keywords/adverse-effect |
| keywords[8].score | 0.508391797542572 |
| keywords[8].display_name | Adverse effect |
| keywords[9].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[9].score | 0.47787800431251526 |
| keywords[9].display_name | Retrospective cohort study |
| keywords[10].id | https://openalex.org/keywords/egfr-inhibitors |
| keywords[10].score | 0.44712668657302856 |
| keywords[10].display_name | EGFR inhibitors |
| keywords[11].id | https://openalex.org/keywords/tyrosine-kinase-inhibitor |
| keywords[11].score | 0.44543248414993286 |
| keywords[11].display_name | Tyrosine-kinase inhibitor |
| keywords[12].id | https://openalex.org/keywords/drug |
| keywords[12].score | 0.42146509885787964 |
| keywords[12].display_name | Drug |
| keywords[13].id | https://openalex.org/keywords/cancer |
| keywords[13].score | 0.338359534740448 |
| keywords[13].display_name | Cancer |
| keywords[14].id | https://openalex.org/keywords/pharmacology |
| keywords[14].score | 0.23474910855293274 |
| keywords[14].display_name | Pharmacology |
| language | en |
| locations[0].id | doi:10.3390/medicina57090929 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S1008817457 |
| locations[0].source.issn | 1010-660X, 1648-9144 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1010-660X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Medicina |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Medicina |
| locations[0].landing_page_url | https://doi.org/10.3390/medicina57090929 |
| locations[1].id | pmid:34577852 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Medicina (Kaunas, Lithuania) |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/34577852 |
| locations[2].id | pmh:oai:mdpi.com:/1648-9144/57/9/929/ |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400947 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | True |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | MDPI (MDPI AG) |
| locations[2].source.host_organization | https://openalex.org/I4210097602 |
| locations[2].source.host_organization_name | Multidisciplinary Digital Publishing Institute (Switzerland) |
| locations[2].source.host_organization_lineage | https://openalex.org/I4210097602 |
| locations[2].license | cc-by |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Medicina |
| locations[2].landing_page_url | https://dx.doi.org/10.3390/medicina57090929 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:8466413 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Medicina (Kaunas) |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8466413 |
| locations[4].id | pmh:oai:europepmc.org:7354878 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S4306400806 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | Europe PMC (PubMed Central) |
| locations[4].source.host_organization | https://openalex.org/I1303153112 |
| locations[4].source.host_organization_name | European Bioinformatics Institute |
| locations[4].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[4].license | other-oa |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | https://openalex.org/licenses/other-oa |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | |
| locations[4].landing_page_url | http://europepmc.org/pmc/articles/PMC8466413 |
| locations[5].id | pmh:oai:doaj.org/article:5e80cb40334f4c798d6ed351f108b7e3 |
| locations[5].is_oa | True |
| locations[5].source.id | https://openalex.org/S4306401280 |
| locations[5].source.issn | |
| locations[5].source.type | repository |
| locations[5].source.is_oa | False |
| locations[5].source.issn_l | |
| locations[5].source.is_core | False |
| locations[5].source.is_in_doaj | False |
| locations[5].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[5].source.host_organization | |
| locations[5].source.host_organization_name | |
| locations[5].source.host_organization_lineage | |
| locations[5].license | cc-by-sa |
| locations[5].pdf_url | |
| locations[5].version | submittedVersion |
| locations[5].raw_type | article |
| locations[5].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[5].is_accepted | False |
| locations[5].is_published | False |
| locations[5].raw_source_name | Medicina, Vol 57, Iss 9, p 929 (2021) |
| locations[5].landing_page_url | https://doaj.org/article/5e80cb40334f4c798d6ed351f108b7e3 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5050567206 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6823-4231 |
| authorships[0].author.display_name | Yutaka Yamada |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210139512 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Ibaraki, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210139512 |
| authorships[0].institutions[0].ror | https://ror.org/03q7y2p06 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210139512 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Ibaraki Prefectural Central Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Yutaka Yamada |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Ibaraki, Japan |
| authorships[1].author.id | https://openalex.org/A5035023922 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3097-4255 |
| authorships[1].author.display_name | Hisao Imai |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I72253084 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Saitama, Japan |
| authorships[1].affiliations[1].raw_affiliation_string | Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I72253084 |
| authorships[1].institutions[0].ror | https://ror.org/02evnh647 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I72253084 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Saitama University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Hisao Imai |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Saitama, Japan, Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan |
| authorships[2].author.id | https://openalex.org/A5109372636 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Tomohide Sugiyama |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210129303 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya 320-0834, Tochigi, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I4210129303 |
| authorships[2].institutions[0].ror | https://ror.org/03eg72e39 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210129303 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Tochigi Cancer Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Tomohide Sugiyama |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya 320-0834, Tochigi, Japan |
| authorships[3].author.id | https://openalex.org/A5043717227 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8710-1960 |
| authorships[3].author.display_name | Hiroyuki Minemura |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I130830085 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I130830085 |
| authorships[3].institutions[0].ror | https://ror.org/012eh0r35 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I130830085 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Fukushima Medical University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Hiroyuki Minemura |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan |
| authorships[4].author.id | https://openalex.org/A5087435965 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Kenya Kanazawa |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I130830085 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I4210146632 |
| authorships[4].affiliations[1].raw_affiliation_string | Clinical Oncology Center, Fukushima Medical University Hospital, Fukushima 960-1295, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I130830085 |
| authorships[4].institutions[0].ror | https://ror.org/012eh0r35 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I130830085 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Fukushima Medical University |
| authorships[4].institutions[1].id | https://openalex.org/I4210146632 |
| authorships[4].institutions[1].ror | https://ror.org/048fx3n07 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210146632 |
| authorships[4].institutions[1].country_code | JP |
| authorships[4].institutions[1].display_name | Fukushima Medical University Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Kenya Kanazawa |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Clinical Oncology Center, Fukushima Medical University Hospital, Fukushima 960-1295, Japan, Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan |
| authorships[5].author.id | https://openalex.org/A5045658682 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3112-4001 |
| authorships[5].author.display_name | Takashi Kasai |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210129303 |
| authorships[5].affiliations[0].raw_affiliation_string | Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya 320-0834, Tochigi, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I4210129303 |
| authorships[5].institutions[0].ror | https://ror.org/03eg72e39 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210129303 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Tochigi Cancer Center |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Takashi Kasai |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya 320-0834, Tochigi, Japan |
| authorships[6].author.id | https://openalex.org/A5037351215 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Koichi Minato |
| authorships[6].affiliations[0].raw_affiliation_string | Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Koichi Minato |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan |
| authorships[7].author.id | https://openalex.org/A5033780369 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-5548-7686 |
| authorships[7].author.display_name | Kyoichi Kaira |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I72253084 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Saitama, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I72253084 |
| authorships[7].institutions[0].ror | https://ror.org/02evnh647 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I72253084 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Saitama University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kyoichi Kaira |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Saitama, Japan |
| authorships[8].author.id | https://openalex.org/A5104022173 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Takayuki Kaburagi |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210139512 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Ibaraki, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210139512 |
| authorships[8].institutions[0].ror | https://ror.org/03q7y2p06 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210139512 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Ibaraki Prefectural Central Hospital |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Takayuki Kaburagi |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Ibaraki, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W2254126652, https://openalex.org/W2418692205, https://openalex.org/W2015104488, https://openalex.org/W3147989365, https://openalex.org/W2280113021, https://openalex.org/W2348666640, https://openalex.org/W2363852307, https://openalex.org/W2184487997, https://openalex.org/W1991551364, https://openalex.org/W2184870804 |
| cited_by_count | 6 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 4 |
| counts_by_year[1].year | 2023 |
| counts_by_year[1].cited_by_count | 1 |
| counts_by_year[2].year | 2022 |
| counts_by_year[2].cited_by_count | 1 |
| locations_count | 6 |
| best_oa_location.id | doi:10.3390/medicina57090929 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S1008817457 |
| best_oa_location.source.issn | 1010-660X, 1648-9144 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1010-660X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Medicina |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Medicina |
| best_oa_location.landing_page_url | https://doi.org/10.3390/medicina57090929 |
| primary_location.id | doi:10.3390/medicina57090929 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S1008817457 |
| primary_location.source.issn | 1010-660X, 1648-9144 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1010-660X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Medicina |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/1648-9144/57/9/929/pdf?version=1632289891 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Medicina |
| primary_location.landing_page_url | https://doi.org/10.3390/medicina57090929 |
| publication_date | 2021-09-03 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2915478882, https://openalex.org/W2151986118, https://openalex.org/W2101751898, https://openalex.org/W2166084034, https://openalex.org/W2132157071, https://openalex.org/W2129360604, https://openalex.org/W2111662961, https://openalex.org/W2210071992, https://openalex.org/W2132870547, https://openalex.org/W1966713566, https://openalex.org/W2032430559, https://openalex.org/W2129685184, https://openalex.org/W2055597038, https://openalex.org/W2061243857, https://openalex.org/W2138434790, https://openalex.org/W2171139285, https://openalex.org/W2096198395, https://openalex.org/W2080648017, https://openalex.org/W2801892650, https://openalex.org/W2088720324, https://openalex.org/W2160040938, https://openalex.org/W2016136864, https://openalex.org/W2019607817, https://openalex.org/W2152905269, https://openalex.org/W2563386033, https://openalex.org/W2553935843, https://openalex.org/W2100409358, https://openalex.org/W6631573400, https://openalex.org/W6640597247, https://openalex.org/W2149733252, https://openalex.org/W3024674456, https://openalex.org/W2151522757, https://openalex.org/W2023698338, https://openalex.org/W2560717039, https://openalex.org/W2554062134, https://openalex.org/W3112157213, https://openalex.org/W3127965499, https://openalex.org/W3121695124, https://openalex.org/W3159238133, https://openalex.org/W3137805818, https://openalex.org/W2152481222, https://openalex.org/W2107263892, https://openalex.org/W2121095198, https://openalex.org/W2953884587, https://openalex.org/W2343874649, https://openalex.org/W2939077612, https://openalex.org/W2978677918, https://openalex.org/W2999203985, https://openalex.org/W2977776394, https://openalex.org/W2998801442, https://openalex.org/W3083988862, https://openalex.org/W1941429289, https://openalex.org/W3176816799, https://openalex.org/W1525536713 |
| referenced_works_count | 54 |
| abstract_inverted_index.2 | 210 |
| abstract_inverted_index.a | 162 |
| abstract_inverted_index.15 | 218 |
| abstract_inverted_index.19 | 132 |
| abstract_inverted_index.21 | 134 |
| abstract_inverted_index.22 | 221 |
| abstract_inverted_index.75 | 44 |
| abstract_inverted_index.78 | 87 |
| abstract_inverted_index.We | 105 |
| abstract_inverted_index.at | 101 |
| abstract_inverted_index.in | 40, 66, 121, 140, 217, 231 |
| abstract_inverted_index.is | 37 |
| abstract_inverted_index.it | 160 |
| abstract_inverted_index.no | 198 |
| abstract_inverted_index.of | 30, 46, 59, 114, 205, 208, 220, 243 |
| abstract_inverted_index.or | 211 |
| abstract_inverted_index.to | 202 |
| abstract_inverted_index.we | 53, 85 |
| abstract_inverted_index.5.3 | 178 |
| abstract_inverted_index.Due | 201 |
| abstract_inverted_index.The | 147 |
| abstract_inverted_index.age | 149 |
| abstract_inverted_index.and | 1, 57, 77, 82, 111, 180, 194, 247 |
| abstract_inverted_index.are | 10 |
| abstract_inverted_index.for | 15, 251 |
| abstract_inverted_index.not | 38 |
| abstract_inverted_index.one | 242 |
| abstract_inverted_index.the | 28, 55, 108, 141, 157, 170, 203, 244 |
| abstract_inverted_index.was | 150, 161, 173, 177, 183, 215, 241 |
| abstract_inverted_index.14.4 | 184 |
| abstract_inverted_index.2008 | 81 |
| abstract_inverted_index.23%, | 174 |
| abstract_inverted_index.79.5 | 151 |
| abstract_inverted_index.EGFR | 25, 50, 74, 95, 129, 239 |
| abstract_inverted_index.age) | 47 |
| abstract_inverted_index.dose | 213 |
| abstract_inverted_index.even | 165 |
| abstract_inverted_index.fact | 158 |
| abstract_inverted_index.four | 102 |
| abstract_inverted_index.lung | 20, 254 |
| abstract_inverted_index.rash | 190 |
| abstract_inverted_index.rate | 172 |
| abstract_inverted_index.safe | 246 |
| abstract_inverted_index.that | 159 |
| abstract_inverted_index.were | 143, 197 |
| abstract_inverted_index.with | 17, 69, 90, 97, 124, 145, 166, 234 |
| abstract_inverted_index.(exon | 131 |
| abstract_inverted_index.(over | 43 |
| abstract_inverted_index.2015, | 84 |
| abstract_inverted_index.April | 80 |
| abstract_inverted_index.L858R | 135 |
| abstract_inverted_index.NSCLC | 71, 92, 126, 236 |
| abstract_inverted_index.There | 196 |
| abstract_inverted_index.after | 33, 62, 117, 227 |
| abstract_inverted_index.grade | 209 |
| abstract_inverted_index.more, | 212 |
| abstract_inverted_index.years | 45, 152 |
| abstract_inverted_index.(range | 153 |
| abstract_inverted_index.Common | 186 |
| abstract_inverted_index.agents | 14 |
| abstract_inverted_index.cancer | 21, 255 |
| abstract_inverted_index.cases. | 222 |
| abstract_inverted_index.cohort | 142 |
| abstract_inverted_index.events | 188, 207 |
| abstract_inverted_index.factor | 5 |
| abstract_inverted_index.growth | 4 |
| abstract_inverted_index.kinase | 7 |
| abstract_inverted_index.median | 148 |
| abstract_inverted_index.safety | 58, 112 |
| abstract_inverted_index.(68.2%) | 219 |
| abstract_inverted_index.(NSCLC) | 22 |
| abstract_inverted_index.75–87 | 154 |
| abstract_inverted_index.Between | 79 |
| abstract_inverted_index.Despite | 156 |
| abstract_inverted_index.adverse | 187, 206 |
| abstract_inverted_index.deaths. | 200 |
| abstract_inverted_index.elderly | 41, 67, 88, 122, 232, 252 |
| abstract_inverted_index.months, | 179 |
| abstract_inverted_index.months. | 185 |
| abstract_inverted_index.options | 250 |
| abstract_inverted_index.overall | 181 |
| abstract_inverted_index.years). | 155 |
| abstract_inverted_index.December | 83 |
| abstract_inverted_index.EGFR-TKI | 31, 35, 60, 64, 99, 115, 119, 167, 224, 229 |
| abstract_inverted_index.However, | 27 |
| abstract_inverted_index.Japanese | 103 |
| abstract_inverted_index.Methods: | 78 |
| abstract_inverted_index.Results: | 137 |
| abstract_inverted_index.advanced | 18, 70, 91, 125, 235 |
| abstract_inverted_index.analyzed | 86 |
| abstract_inverted_index.clinical | 109 |
| abstract_inverted_index.included | 189 |
| abstract_inverted_index.limited, | 245 |
| abstract_inverted_index.patients | 16, 42, 68, 89, 123, 139, 233 |
| abstract_inverted_index.profiles | 113 |
| abstract_inverted_index.response | 171 |
| abstract_inverted_index.survival | 176, 182 |
| abstract_inverted_index.EGFR-TKI. | 146 |
| abstract_inverted_index.Epidermal | 3 |
| abstract_inverted_index.Materials | 76 |
| abstract_inverted_index.analysis, | 164 |
| abstract_inverted_index.anorexia. | 195 |
| abstract_inverted_index.diarrhea, | 193 |
| abstract_inverted_index.effective | 11, 248 |
| abstract_inverted_index.evaluated | 107 |
| abstract_inverted_index.harboring | 23, 48, 72, 93, 127, 237 |
| abstract_inverted_index.mutations | 96, 130, 240 |
| abstract_inverted_index.patients. | 256 |
| abstract_inverted_index.performed | 216 |
| abstract_inverted_index.reduction | 214 |
| abstract_inverted_index.treatment | 36, 65, 100, 120, 169, 226, 230, 249 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.Therefore, | 52 |
| abstract_inverted_index.Twenty-two | 138 |
| abstract_inverted_index.acneiform, | 191 |
| abstract_inverted_index.first-line | 12, 34, 63, 98, 118, 228 |
| abstract_inverted_index.inhibitors | 8 |
| abstract_inverted_index.mutation). | 136 |
| abstract_inverted_index.mutations. | 26, 51, 75 |
| abstract_inverted_index.occurrence | 204 |
| abstract_inverted_index.sufficient | 39 |
| abstract_inverted_index.(EGFR-TKIs) | 9 |
| abstract_inverted_index.Objectives: | 2 |
| abstract_inverted_index.paronychia, | 192 |
| abstract_inverted_index.rechallenge | 32, 61, 116, 168, 225 |
| abstract_inverted_index.Conclusions: | 223 |
| abstract_inverted_index.investigated | 54 |
| abstract_inverted_index.rechallenged | 144 |
| abstract_inverted_index.EGFR-positive | 253 |
| abstract_inverted_index.deletion/exon | 133 |
| abstract_inverted_index.effectiveness | 29, 56, 110 |
| abstract_inverted_index.institutions. | 104 |
| abstract_inverted_index.retrospective | 163 |
| abstract_inverted_index.drug-sensitive | 24, 49, 73, 94, 128, 238 |
| abstract_inverted_index.non-small-cell | 19 |
| abstract_inverted_index.retrospectively | 106 |
| abstract_inverted_index.chemotherapeutic | 13 |
| abstract_inverted_index.progression-free | 175 |
| abstract_inverted_index.treatment-related | 199 |
| abstract_inverted_index.receptor–tyrosine | 6 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5050567206 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I4210139512 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8799999952316284 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.75843279 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |